Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Azilect
Generic Name
Rasagiline Mesylate
Active Ingredient
RasagilineCategory
Other
Salt Form
Mesylate
Variants
2
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Azilect, you must consult a qualified healthcare professional.
Detailed information about Azilect
Rasagiline is a potent, irreversible monoamine oxidase type B (MAO-B) inhibitor used to treat the symptoms of Parkinson's disease, either as a standalone therapy or in combination with levodopa.
For the treatment of Parkinson's disease, the standard adult dosage of Rasagiline is as follows:
Rasagiline is NOT approved for use in pediatric patients. The safety and effectiveness of Rasagiline in children and adolescents under the age of 18 have not been established. Parkinson's disease is extremely rare in this population, and the pharmacological effects of MAO-B inhibitors on developing neurological systems are not well understood.
For patients with mild, moderate, or severe renal (kidney) impairment, no dosage adjustment of Rasagiline is typically required. Because Rasagiline is primarily metabolized by the liver before excretion, kidney function has a minimal impact on the drug's active levels. However, clinical data in patients with end-stage renal disease is limited.
Your liver plays a vital role in clearing Rasagiline from your body.
No specific dosage adjustment is required for elderly patients (over 65). However, older patients may be more sensitive to side effects such as orthostatic hypotension (a drop in blood pressure when standing up) and hallucinations. Healthcare providers typically monitor elderly patients more closely during dose escalation.
If you miss a dose of Rasagiline, skip the missed dose and take your next dose at the regular scheduled time. Do not take two doses at once to make up for a missed one, as this increases the risk of side effects and blood pressure spikes. If you miss several doses, contact your healthcare provider for guidance on restarting the medication.
Symptoms of a Rasagiline overdose may resemble those of non-selective MAO inhibitors and can be life-threatening. Potential signs include:
In case of a suspected overdose, seek emergency medical attention immediately or contact a Poison Control Center. There is no specific antidote for Rasagiline; treatment is supportive and focuses on managing blood pressure and body temperature.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without direct medical guidance.
In clinical trials, the side effect profile of Rasagiline differed depending on whether it was used alone or with levodopa. Common side effects include:
Rasagiline is a powerful neurological medication that requires careful monitoring. Patients must be aware that while it is highly selective for MAO-B, this selectivity is dose-dependent. Taking more than the prescribed dose can cause it to act like a non-selective MAO inhibitor, significantly increasing the risk of dangerous drug and food interactions.
There are no FDA black box warnings for Rasagiline as of 2026. However, the FDA requires prominent warnings regarding the risk of Hypertensive Crisis and Serotonin Syndrome in the prescribing information.
Although Rasagiline is selective, it can still cause a rapid, life-threatening rise in blood pressure if taken with foods containing high amounts of tyramine (e.g., aged cheeses, cured meats, fava beans, draft beer). Patients should be educated on a low-tyramine diet. If you experience a sudden, 'thunderclap' headache, seek emergency care immediately.
The following medications must NEVER be used with Rasagiline due to the risk of life-threatening reactions:
Rasagiline must NEVER be used in the following circumstances:
Rasagiline was formerly classified as Category C. There are no adequate and well-controlled studies of Rasagiline in pregnant women. Animal studies (rats and rabbits) have shown some evidence of increased fetal death and decreased fetal body weight at doses much higher than those used in humans.
Rasagiline should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. If you become pregnant while taking Rasagiline, notify your neurologist immediately. It is not currently recommended for use in women of childbearing potential who are not using effective contraception.
It is not known whether Rasagiline is excreted in human milk. However, because many drugs are excreted in human milk and because animal studies have shown that Rasagiline can inhibit prolactin secretion (the hormone that stimulates milk production), caution is advised. The risk to the nursing infant versus the benefit of the drug to the mother must be carefully considered. Most clinicians recommend using alternative treatments or formula feeding while on Rasagiline.
Rasagiline is an irreversible, selective inhibitor of monoamine oxidase type B (MAO-B). MAO-B is an enzyme located in the mitochondrial outer membrane of cells, particularly within the striatum of the brain. Its primary role is the oxidative deamination (breakdown) of dopamine.
At the molecular level, Rasagiline contains a propargylamine moiety that binds covalently to the N-5 atom of the flavin adenine dinucleotide (FAD) cofactor within the MAO-B enzyme. This creates a stable, inactive complex. By 'locking' the enzyme, Rasagiline prevents it from breaking down dopamine. This results in increased extracellular levels of dopamine in the synaptic cleft, enhancing dopaminergic transmission and alleviating the motor deficits associated with Parkinson's disease.
Rasagiline's pharmacodynamic effect is characterized by a rapid onset of enzyme inhibition. Studies of platelet MAO-B activity (used as a surrogate for brain activity) show that a single 1 mg dose inhibits more than 80% of the enzyme within hours. With daily dosing, inhibition exceeds 95%. Because the bond is irreversible, the effect lasts until new enzyme molecules are synthesized by the body, which typically takes 1 to 2 weeks after the last dose. This explains why drug interactions can still occur long after the medication is stopped.
Common questions about Azilect
Rasagiline is primarily used to treat the symptoms of Parkinson's disease, such as tremors, stiffness, and slowness of movement. It can be used alone in the early stages of the disease or in combination with levodopa/carbidopa in more advanced stages. When used with levodopa, it helps reduce 'off' periods where the effects of other medications wear off. It works by increasing the amount of dopamine available in the brain. Your healthcare provider will determine the best stage of your treatment to introduce this medication.
The most common side effects include headache, joint pain (arthralgia), and dizziness. When taken with levodopa, patients frequently report dyskinesia (involuntary movements) and accidental injury. Other common issues include nausea, weight loss, and orthostatic hypotension, which is a drop in blood pressure when standing. Most of these side effects are manageable, but you should report any persistent or worsening symptoms to your doctor. Some patients may also experience hallucinations or intense urges, such as compulsive gambling.
It is generally recommended to avoid or strictly limit alcohol while taking Rasagiline. Alcohol can worsen side effects like dizziness, drowsiness, and lightheadedness, increasing the risk of falls. Furthermore, certain alcoholic beverages, particularly tap beers and some red wines, contain tyramine. Combining tyramine with an MAO inhibitor like Rasagiline can lead to a dangerous spike in blood pressure. Always discuss your alcohol consumption habits with your healthcare provider before starting this medication.
The safety of Rasagiline during pregnancy has not been established in human studies. Animal data suggests that high doses may have adverse effects on fetal development, though these doses were much higher than human equivalents. Because of the lack of human data, Rasagiline is only recommended during pregnancy if the benefits clearly outweigh the potential risks to the fetus. Women who are pregnant or planning to become pregnant should consult their neurologist to discuss alternative treatment options. It is also unknown if the drug passes into breast milk, so breastfeeding is generally discouraged.
While Rasagiline begins inhibiting the MAO-B enzyme within hours of the first dose, it may take several weeks to notice a significant improvement in Parkinson's symptoms. Most clinical trials observed measurable benefits within 4 to 12 weeks of consistent daily use. It is important to continue taking the medication exactly as prescribed, even if you do not feel an immediate difference. Your doctor will likely evaluate your progress after the first few months of therapy to determine if the dose is effective.
No, you should not stop taking Rasagiline suddenly without consulting your healthcare provider. Abruptly discontinuing the medication can cause a rapid return of Parkinson's symptoms, making it difficult to move or perform daily tasks. In rare cases, sudden withdrawal of dopaminergic medications can lead to a serious condition called Neuroleptic Malignant Syndrome-like complex, which involves high fever and muscle rigidity. If the medication needs to be stopped, your doctor will guide you through a safe, gradual tapering process.
If you miss a dose, you should skip the missed dose entirely and take your next dose at the regularly scheduled time. Never take two doses at once to 'catch up,' as this significantly increases the risk of side effects and dangerous blood pressure elevations. To help you remember your medication, try taking it at the same time every day, such as with breakfast. If you find yourself frequently missing doses, speak with your doctor or pharmacist about using a pill organizer or a reminder app.
Weight gain is not a typical side effect of Rasagiline; in fact, weight loss was more commonly reported in clinical trials, especially when the drug was used as an add-on to levodopa. If you notice significant or rapid changes in your weight, it may be due to other factors, such as changes in your activity level, other medications, or the Parkinson's disease itself. You should discuss any significant weight changes with your healthcare team to ensure your nutritional needs are being met and to rule out other underlying causes.
Rasagiline has many serious drug interactions, so it must be used with caution alongside other medications. It should never be taken with other MAO inhibitors, certain pain medications like meperidine or tramadol, or the herbal supplement St. John's Wort. Caution is also required when taking it with antidepressants (SSRIs or SNRIs) due to the risk of Serotonin Syndrome. Always provide your doctor and pharmacist with a complete list of all prescription drugs, over-the-counter medicines, vitamins, and herbal supplements you are currently taking.
Yes, Rasagiline is available as a generic medication, which is typically more cost-effective than the brand-name version, Azilect. Generic versions are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug. They must also prove bioequivalence, meaning they work the same way in the body. If you are concerned about the cost of your medication, ask your pharmacist or healthcare provider if a generic version of Rasagiline is appropriate for you.
Other drugs with the same active ingredient (Rasagiline)
> Warning: Stop taking Rasagiline and call your doctor immediately if you experience any of these serious symptoms.
With prolonged use, the most significant concerns involve the management of motor complications. While Rasagiline helps with 'off' time, the long-term increase in dopamine can lead to persistent dyskinesia that may require adjustments to other Parkinson's medications. Additionally, the risk of impulse control disorders may persist or emerge at any point during long-term therapy. Regular monitoring of blood pressure and mental health is necessary for as long as the patient remains on the drug.
No FDA black box warnings currently exist for Rasagiline. However, it carries significant 'Warnings and Precautions' regarding hypertensive crisis and serotonin syndrome, which are treated with the same level of clinical gravity as black box warnings in practice.
Report any unusual symptoms to your healthcare provider. Your doctor can help determine if a side effect is related to Rasagiline or to the underlying progression of Parkinson's disease.
Combining Rasagiline with other drugs that increase serotonin (SSRIs, SNRIs, tricyclic antidepressants, certain pain medications) can lead to Serotonin Syndrome. This is a medical emergency. Do not start any new medication, including over-the-counter cold medicines or supplements, without checking with your pharmacist.
Patients treated with Rasagiline have reported falling asleep without prior warning while engaged in activities of daily living, including the operation of motor vehicles. This can occur at any time during treatment. If you experience increased daytime sleepiness, you must avoid driving and notify your doctor.
Rasagiline can cause orthostatic hypotension (low blood pressure upon standing). This is especially risky in the first month of treatment or when the dose is increased. Patients should rise slowly from a sitting or lying position to prevent falls and fractures.
Rasagiline may cause sudden sleep onset, dizziness, or hallucinations. You should not drive or operate heavy machinery until you know how the medication affects you. If you feel sleepy during the day, do not drive.
Alcohol should be avoided or strictly limited. Alcohol can increase the sedative effects of Rasagiline and may also contribute to unpredictable blood pressure changes. Some alcoholic beverages (like tap beers or certain red wines) also contain tyramine, which increases the risk of a hypertensive crisis.
Do not stop taking Rasagiline abruptly. While it does not have a traditional 'withdrawal' syndrome like benzodiazepines, stopping it suddenly can lead to a rapid return of Parkinson's symptoms or, in rare cases, a condition resembling Neuroleptic Malignant Syndrome (characterized by high fever, muscle rigidity, and autonomic instability). If the drug must be stopped, your doctor will provide a tapering schedule.
> Important: Discuss all your medical conditions, especially liver disease and any history of mental illness, with your healthcare provider before starting Rasagiline.
Rasagiline is not known to significantly interfere with most common laboratory tests (such as basic metabolic panels or complete blood counts). However, always inform your laboratory technician and doctor that you are taking an MAO-B inhibitor, as it may theoretically affect certain tests for catecholamines (hormones made by the adrenal glands).
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even 'natural' products can have dangerous interactions with Rasagiline.
These are conditions where the doctor will carefully weigh the risks versus the benefits:
There is no established cross-sensitivity between Rasagiline and other classes of Parkinson's medications (like dopamine agonists or COMT inhibitors). However, patients who have had severe reactions to Selegiline (another MAO-B inhibitor) should be monitored closely, as they may share similar sensitivities to the chemical structure of propargylamines.
> Important: Your healthcare provider will evaluate your complete medical history, including liver function and current medications, before prescribing Rasagiline.
Rasagiline is not approved for use in children. The safety profile has not been tested in patients under 18. Because Parkinson's disease is a condition of the aging brain, there is no clinical indication for its use in pediatric populations.
In clinical trials, approximately 60% of patients were 65 years or older. While no overall differences in effectiveness were observed between these patients and younger patients, the elderly are at a higher risk for:
No dose adjustment is necessary for patients with kidney disease. Rasagiline's clearance is not significantly affected by renal function. However, for patients on dialysis, the drug has not been extensively studied, and caution is warranted.
This is the most critical special population for Rasagiline. The liver is the primary site of metabolism.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have a history of liver disease.
| Parameter | Value |
|---|---|
| Bioavailability | ~36% (Significant first-pass metabolism) |
| Protein Binding | 88% - 94% (Primarily to Albumin) |
| Half-life | 1.3 - 3.0 Hours (Plasma); Biological effect is 1-2 weeks |
| Tmax | ~1 Hour |
| Metabolism | Hepatic via CYP1A2 |
| Excretion | Renal 62%, Fecal 7% |
Rasagiline is classified as a Selective Monoamine Oxidase Type B Inhibitor. It belongs to the propargylamine family. Related medications include Selegiline (Eldepryl, Zelapar) and Safinamide (Xadago). Unlike Selegiline, Rasagiline is not metabolized into L-amphetamine or L-methamphetamine, which is a key clinical distinction that often results in fewer cardiovascular and sleep-related side effects.